iShares Nasdaq Biotechnology ETF (IBB) Shares Bought by Lido Advisors LLC

Lido Advisors LLC lifted its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 25.9% during the third quarter, Holdings Channel reports. The firm owned 4,256 shares of the financial services provider’s stock after purchasing an additional 875 shares during the period. Lido Advisors LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $519,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of IBB. Paloma Partners Management Co grew its holdings in shares of iShares Nasdaq Biotechnology ETF by 1,643.3% in the second quarter. Paloma Partners Management Co now owns 323,373 shares of the financial services provider’s stock worth $35,513,000 after purchasing an additional 304,824 shares during the last quarter. Credit Suisse AG grew its holdings in shares of iShares Nasdaq Biotechnology ETF by 1,228.8% in the third quarter. Credit Suisse AG now owns 224,782 shares of the financial services provider’s stock worth $27,410,000 after purchasing an additional 207,866 shares during the last quarter. Commerzbank Aktiengesellschaft FI grew its holdings in shares of iShares Nasdaq Biotechnology ETF by 54.0% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 585,506 shares of the financial services provider’s stock worth $64,300,000 after purchasing an additional 205,200 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of iShares Nasdaq Biotechnology ETF by 36.2% in the third quarter. Alliancebernstein L.P. now owns 737,179 shares of the financial services provider’s stock worth $89,892,000 after purchasing an additional 195,746 shares during the last quarter. Finally, Aviance Capital Management LLC grew its holdings in iShares Nasdaq Biotechnology ETF by 730.2% during the 3rd quarter. Aviance Capital Management LLC now owns 147,849 shares of the financial services provider’s stock worth $18,029,000 after acquiring an additional 130,040 shares in the last quarter. Hedge funds and other institutional investors own 63.65% of the company’s stock.

Shares of iShares Nasdaq Biotechnology ETF stock opened at $103.64 on Friday. iShares Nasdaq Biotechnology ETF has a 1 year low of $100.22 and a 1 year high of $122.97.

COPYRIGHT VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/08/ishares-nasdaq-biotechnology-etf-ibb-shares-bought-by-lido-advisors-llc.html.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More: Why do company’s buyback their stock?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply